Comparative effectiveness research under the patient protection and affordable care act: Can new bottles accommodate old wine?

American Journal of Law and Medicine

Volumn 37, Issue 4, 2011, Pages 522-566

  Kinney, Eleanor D ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPARATIVE EFFECTIVENESS; HEALTH CARE POLICY; HEALTH SERVICES RESEARCH; HUMAN; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; UNITED STATES;

COMPARATIVE EFFECTIVENESS RESEARCH; HEALTH SERVICES RESEARCH; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT PROTECTION AND AFFORDABLE CARE ACT; UNITED STATES;

EID: 84855773633     PISSN: 00988588     EISSN: None     Source Type: Journal    
DOI: 10.1177/009885881103700402     Document Type: Article

References (106)

1. A Short History of the National Institutes of Health: WWII and the Ransdell Act of 1930, NAT'L INSTS. OF HEALTH, http://history.nih.gov/exhibits/ history/docs/page-04.html (last visited Oct. 1, 2010).
2. Hamilton Moses et al., Financial Anatomy of Biomedical Research, 294 JAMA 1333, 1335 (2005);
3. Darren E. Zinner & Eric G. Campbell, Life-Science Research Within US Academic Medical Centers, 302 JAMA 969, 973-75 (2009).
4. Proposed Medicare Reimbursement Formula: Hearings Before the S. Comm. on Finance, 89th Cong. 4 (1966).
5. Marian Gornick et al., Twenty Years of Medicare and Medicaid: Covered Populations, Use of Benefits, and Program Expenditures, 6 HEALTH CARE FIN. REV. 13 (Supp. 1985).
6. THE ROLE OF HEALTH INSURANCE IN THE HEALTH SERVICES SECTOR (Richard N. Rosett ed., 1976);
7. Kenneth J. Arrow, The Economics of Moral Hazard: Further Comment, 58 AM. ECON. REV. 537 (1968).
8. ROBERT E. ADLER, MEDICAL FIRSTS: FROM HIPPOCRATES TO THE HUMAN GENOME (2004);
9. JOHN G. SIMMONS, DOCTORS AND DISCOVERIES: LIVES THAT CREATED TODAY'S MEDICINE (2004).
10. ALAN B. COHEN & RUTH S. HANFT, TECHNOLOGY IN AMERICAN HEALTH CARE: POLICY DIRECTIONS FOR EFFECTIVE EVALUATION AND MANAGEMENT (2004);
11. Harvey Brooks & Raymond Bowers, The Assessment of Technology, 222 SCI. AM. 13, 14 (1970).
12. Dennis Cotter, The National Center for Health Care Technology: Lessons Learned, HEALTH AFF. BLOG (Jan. 22, 2009, 6:54 AM), http://healthaffairs.org/ blog/2009/01/22/the-national-center-forhealth- care-technology-lessons-learned/.
13. Eleanor D. Kinney, National Coverage Policy under the Medicare Program: Problems and Proposals for Change, 32 ST. LOUIS U. L.J. 869, 881 (1987-1988).
14. Ezekiel J. Emanuel, Victor R. Fuchs & Alan M. Garber, Essential Elements of a Technology and Outcomes Assessment Initiative, 298 JAMA 1323 (2007).
15. Evelyn Flook, Health Services Research and Development, 84 PUB. HEALTH REP. 358, 359-60 (1969).
16. Robert H. Brook & Kathleen N. Lohr, Monitoring Quality of Care in the Medicare Program, 258 JAMA 3138 (1987);
17. Paul M. Ellwood, Shattuck Lecture - Outcomes Management: A Technology of Patient Experience, 318 NEW ENG. J. MED. 1549 (1988).
18. Robert H. Brook & Kathleen N. Lohr, Efficacy, Effectiveness, Variations, and Quality: Boundary-Crossing Research, 23 MED. CARE 710, 718-19 (1985);
19. David M. Eddy, Variation in Physician Practice: The Role of Uncertainty, 3 HEALTH AFF. 74, 85-86 (1984);
20. David M. Eddy & John Billings, The Quality of Medical Evidence: Implications for Quality of Care, 7 HEALTH AFF. 19, 27(1988).
21. William L. Roper et al., Effectiveness in Health Care: An Initiative to Evaluate and Improve Medical Practice, 319 NEW ENG. J. MED. 1197, 1198-99 (1988);
22. William L. Roper & Glenn M. Hackbarth, HCFA 's Agenda for Promoting High-Quality Care, 7 HEALTH AFF. 91, 95-97 (1988).
23. PAUL L. JOSKOW, CONTROLLING HOSPITAL COSTS: THE ROLE OF GOVERNMENT REGULATION (1981);
24. Martin S. Feldstein, Hospital Cost Inflation: A Study of Nonprofit Price Dynamics, 61(5) AM. ECON. REV. 853, 870 (1971).
25. John E. Wennberg et al., Professional Uncertainty and the Problem of Supplier-Induced Demand, 16 Soc. SCI. & MED. 811 (1982);
26. John E. Wennberg & John Gittelsohn, Small Area Variation in Health Care Delivery, 182 SCI. 1102, 1004 (1973);
27. John E. Wennberg & John Gittelsohn, Variations in Medical Care Among Small Areas, 246 SCI. AM. 120, 122-23 (1982).
28. U.S. DEP'T HEALTH AND HUMAN SERVS., AGENCY FOR HEALTH CARE POL'Y AND RES., AHCPR PROGRAM NOTE: CLINICAL GUIDELINE DEVELOPMENT (1990);
29. Bradford H. Gray, The Legislature Battle over Health Services Research, 11 HEALTH REG. 38, 39 (1992).
30. John E. Wennberg, The More Things Change . . . : The Federal Government's Role In The Evaluative Sciences, HEALTH AFF. W3-309 (June 25, 2003), http://content.healthaffairs.org/content/ early/2003/06/25/h rthaff.w3.308.full.pdf.
31. Clifton R. Gaus, Perspective: An Insider's Perspective on the Near-Death Experience of AHCPR, HEALTH AFF. W3-311 (June 25, 2003), http://content. healthaffairs.org/content/early/2003/ 06/25/hlthaff.w3.31 l.full.pdf;
32. Bradford H. Gray, Michael K. Gusmano & Sara R. Collins, AHCPR and the Changing Politics of Health Services Research, HEALTH AFF. W3-283 (June 25, 2003), http://content.healthaffairs.org/content/early/2003/06/25/hlthaff.w3.283. full.pdf.
33. STANLEY J. BIGOS ET AL., AGENCY FOR HEALTH CARE POL'Y AND RES. PUBLICATION NO. 95-0642, CLINICAL PRACTICE GUIDELINES, ACUTE LOW BACK PROBLEMS IN ADULTS: CLINICAL PRACTICE GUIDELINE NO. 14 (1994);
34. Richard A. Deyo, Back Pain Patient Outcomes Assessment Team (BOAT), AGENCY FOR HEALTHCARE QUALITY AND RES., http://www.ahcpr.gov/clinic/medtep/ backpain.htm (last visited Sept. 30, 2010).
35. Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations for 1996: Hearings Before the Subcomm. of the House Comm. on Appropriations, 104th Cong. 170-72 (1995);
36. Neil A. Lewis, Agency's Report Provokes a Revolt, N.Y. TIMES, Sept. 14, 1995, at A16.
37. Marc L. Berger & Milton C. Weinstein, Comparative Effectiveness: Asking the Right Questions, Choosing the Right Method, 24 HEALTH AFF. 128, 128 (2005).
38. John P. Bunker et al., Evaluation of Medical-Technology Strategies: Effects of Coverage and Reimbursement, 306 NEW ENG. J. MED. 620, 621 (1982);
39. John P. Bunker et al., Evaluation of Medical-Technology Strategies: Proposal for an Institute for Health-Care Evaluation, 306 NEW ENG. J. MED. 687, 688 (1982);
40. Barbara Greenberg & Robert A. Derzon, Determining Health Insurance Coverage of Technology: Problems and Options, 19 MED. CARE 967 (1981);
41. John K. Iglehart, The Cost and Regulation of Medical-Technology: Future Policy Directions, 55 MlLBANK MEMORIAL FUND Q. HEALTH & SOC'Y 25 (1977).
42. Ward Casscells, Heart Transplantation: Recent Policy Developments, 315 NEW ENG. J. MED. 1365 (1986).
43. Darrel J. Grinstead, Evolution of the Medicare Coverage Policy-Making Process, in GUIDE To MEDICARE COVERAGE DECISION-MAKING AND APPEALS 1,9-13 (Eleanor D. Kinney ed., 2002).
44. Bradley Merrill Thompson & Brian A. Dahl, The Food and Drug Administration Review Process for Medical Devices, in GUIDE To MEDICARE COVERAGE DECISION-MAKING AND APPEALS, at 41.
45. Sean R. Tunis, Why Medicare Has Not Established Criteria for Coverage Decisions, 350 NEW ENG. J. MED. 2196 (2004).
46. Susan B. Foote, Focus on Locus: Evolution of Medicare's Local Coverage Policy, 22 HEALTH AFF., 137, 138 (2003).
47. Susan B. Foote, Why Medicare Cannot Promulgate a National Coverage Rule: A Case of Regula Mortis, 27 J. HEALTH POL., POL'Y & L. 707, 708 (2002).
48. Alan M. Garber, Cost-Effectiveness and Evidence Evaluation as Criteria for Coverage Policy, HEALTH AFF. W4-284, W4-288 to -89 (2004), http://content.healthaffairs.org/ content/early/2004/05/19/hlthaff.w4.284. citation;
49. Muriel R. Gillick, Medicare Coverage for Technological Innovations, 350 NEW ENG. J. MED. 719, 720 (2004);
50. Peter J. Neumann, Why Don't Americans Use Cost-Effectiveness Analysis?, 10 AM. J. MANAGED CARE 308 (2004);
51. Sean R. Tunis, Why Medicare Has Not Established Criteria for Coverage Decision, 350 NEW ENG. J. MED. 2196, 2197-98 (2004);
52. Sean R. Tunis, Economic Analysis in Health Care Decisions, 10 AM. J. MANAGED CARE 301, 301 (2004).
53. Marthe R. Gold et al., Medicare and Cost-Effectiveness Analysis: Time to Ask the Taxpayers, 26 HEALTH AFF. 1399, 1400-02 (2007);
54. Peter J. Neumann et al., Medicare and Cost- Effectiveness Analysis, 353 NEW ENG. J. MED. 1516, 1519-20 (2005);
55. Jacqueline Fox, Medicare Should, but Cannot, Consider Cost: Legal Impediments to Sound Policy, 53 BUFF. L. REV. 577, 578 (2005).
56. Susan B. Foote & Robert J. Town, Implementing Evidence-Based Medicine Through Medicare Coverage Decisions, 26 HEALTH AFF. 1634, 1635-36 (2007);
57. Peter J. Neumann et al., Medicare's National Coverage Decisions for Technologies, 1999-2007, 27 HEALTH AFF. 1620, 1621-22 (2008);
58. Sean R. Tunis et al., Federal Initiatives to Support Rapid Learning About New Technologies, 26 HEALTH AFF. wl40, wl41-42 (2007).
59. Tanisha Carino et al., Medicare's Coverage of Colorectal Cancer Drugs: A Case Study in Evidence Development and Policy, 25 HEALTH AFF. 1231, 1237 (2006);
60. Tanisha Carino et al., Using Clinical Trials as a Condition of Coverage: Lessons from the National Emphysema Treatment Trial, 1 CLINICAL TRIALS 108, 109 (2004);
61. Patrick H. Conway & Carolyn Clancy, Charting a Path from Comparative Effectiveness Funding to Improved Patient-Centered Health Care, 303 JAMA 985, 985 (2010);
62. Patrick H. Conway & Carolyn Clancy, Transformation of Health Care at the Front Line, 301 JAMA 763, 765 (2009);
63. Margaret O'Kane et al., Crossroads in Quality, 27 HEALTH AFF. 749, 751-55 (2008);
64. J. W. Rowe et al., The Emerging Context for Advances in Comparative Effectiveness Assessment, 25 HEALTH AFF. w593, w595 (2006),http://content. healthaffairs.Org/content/25/6/w593.full.pdf+html
65. Gail R. Wilensky, Developing a Center for Comparative Effectiveness Information, 25 HEALTH AFF. w572, w577 (2006), http://content.healthaffairs.org/ content/25/6/w572.1ong.
66. David Atkins, Creating and Synthesizing Evidence with Decision Makers in Mind: Integrating Evidence from Clinical Trials and Other Study Designs, 45 MED. CARE S16, S17-S20 (Supp. 2007);
67. Susan D. Horn & Julie Gassaway, Practice-Based Evidence Study Design for Comparative Effectiveness Research, 45 MED. CARE S50, S52-S55 (Supp. 2007);
68. Kathleen N. Lohr, Emerging Methods in Comparative Effectiveness and Safety: Symposium Overview and Summary, 45 MED. CARE S5, S6-S7 (Supp. 2007);
69. Sebastian Schneeweiss & Jerry Avorn, A Review of Uses of Health Care Utilization Databases for Epidemiologic Research on Therapeutics, 58 J. CLINICAL EPIDEMIOLOGY 323, 324-34 (2005);
70. Brian L. Strom, Methodologic Challenges to Studying Patient Safety and Comparative Effectiveness, 45 MED. CARE S13, S13-S15 (Supp. 2007).
71. Neil Kirschner et al., Information on Cost-Effectiveness: An Essential Product of a National Comparative Effectiveness Program, 148 ANNALS OF INTERNAL MED. 956 (2008);
72. Gail R. Wilensky, Cost-Effectiveness Information: Yes, It's Important, but Keep It Separate, Please!, 148 ANNALS OF INTERNAL MED. 967,967-8 (2008). (Pubitemid 351860830)
73. RICHARD HODES, NAT'L INST, ON AGING, ROLE OF THE NIH IN COMPARATIVE EFFECTIVENESS (2009), available at http://www.ctsaweb.org/uploadedfiles/4- CER%20Research-Hodes.pdf.
74. Gerald L. Andriole et al., Mortality Results from a Randomized Prostate-Cancer Screening Trial, 360 NEW ENG. J. MED 1310 (2009);
75. Gust H. Bardy et al., Amiodarone or an Implantable Cardioverter- Defibrillator for Congestive Heart Failure, 352 NEW ENG. J. MED 225 (2005);
76. Jeffrey A. Lieberman et al., Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia, 353 NEW ENG. J. MED. 1209 (2005);
77. Patrick H. Conway & Carolyn Clancy, Comparative-Effectiveness Research-Implications of the Federal Coordinating Council's Report, 361 NEW ENG. J. MED. 328 (2009).
78. John K. Iglehart, Prioritizing Comparative-Effectiveness Research-IOM Recommendations, 361 NEW ENG. J. MED. 325, 325 (2009);
79. Harold C. Sox & Sidney Greenfield, Comparative Effectiveness Research: A Report From the Institute of Medicine, 153 ANNALS OF INTERNAL MED. 203, 203 (2009).
80. Sarah Palin, Statement on the Current Health Reform Debate, Note on FACEBOOK (Aug. 7, 2009, 4:26 PM), http://www.facebook.com/note.php?note-id= l13851103434.
81. Ezra Klein, Ezra Klein Interviews Ezekiel Emanuel on 'Death Panels' and D.C. Food, WASH. POST (Aug. 16, 2009), http://www.washingtonpost.com/wp-dyn/ content/article/2009/08/14/ AR2009081401666.html.
82. Betsy McCaughey, Deadly Doctors, O Advisers Want to Ration Care, N.Y. POST, July 24, 2009, http://www.nypost.eom/p/news/opinion/opedcolumnists/itera- PU6S0iok2FbS368B7d7mAM.
83. Carolyn Clancy & Francis S. Collins, Patient-Centered Outcomes Research Institute: The Intersection of Science and Health Care, 2 SCI. TRANSLATIONAL MED. 37 (2010).
84. Eleanor D. Kinney, The Brave New World of Medical Standards of Care, 29 J.L. MED. & ETHICS 323, 325 (2002);
85. Eleanor D. Kinney & Marilyn M. Wilder, Medical Standard Setting in the Current Malpractice Environment: Problems and Possibilities, 22 U.C. DAVIS L. REV. 421, 423 (1989).
86. Mark R. Chassin, Standards of Care in Medicine, 25 INQUIRY 437, 442 (1988)
87. Linda Johnson White & John Ball, Clinical Efficacy Assessment Project of the American College of Physicians, 1 INT'L J. TECH. ASSESSMENT IN HEALTH CARE 67 (1985)
88. John Kelly & Joanna Swartwout, Development of Practice Parameters by Physician Organizations, 16 QUALITY REV. BULL. 54, 54 (1990);
89. J. Sanford Schwartz, The Role of Professional Medical Societies in Reducing Practice Variations, 3 HEALTH AFF. 90, 92-96 (1984)
90. Miriam J. Laugesen and Thomas Rice, Is the Doctor In? The Evolving Role of Organized Medicine in Health Policy, 28 J. HEALTH POL., POL'Y AND L. 289 (2003).
91. Eleanor D. Kinney, The New Medicare Coverage Decision-Making and Appeal Procedures: Can Process Meet the Challenge of New Medical Technology?, 60 WASH. & LEE L. REV. 1461, 1501-02 (2003)
92. JENNIFER O'SULLIVAN, CONG. RES. SERV., RL 34280, MEDICARE PART D PRESCRIPTION DRUG BENEFIT: A PRIMER (2008), available at http://aging.senate. gov/crs/medicarel2.pdf;
93. John K. Iglehart, The New Medicare Prescription-Drug Benefit-A Pure Power Play, 350 NEW ENG. J. MED. 826 (2004).
94. Federal Food, Drug, and Cosmetic Act, Pub. L. No. 75-717, 52 Stat. 1040 (2006) (codified as amended 21 U.S.C. § 301 et seq.).
95. Scott Gottlieb, The FDA Should not Mandate Comparative-Effectiveness Trials, 5 HEALTH POL'Y OUTLOOK 1 (2011), http://www.aei.org/docLib/HPO-2011-05- g.pdf.
96. Christopher P. Adams & Van V. Brantner, Estimating The Cost Of New Drug Development: Is It Really $802 Million?, 25 HEALTH AFF. 420, 420 (2006).
97. Ernst R. Berndt, Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price, 16 J. ECON. PERSP. 45, 59 (2002).
98. Aidan Hollis, Me-Too Drugs: Is There A Problem?, World Health Organization 1, 1 (2004), http://www.who.int/intellectualproperty/topics/ip/Me- tooDrugs-Hollisl.pdf.
99. Eleanor D. Kinney, Behind the Veil Where the Action Is: Private Policy Making and American Health Care, 51 ADMIN. L. REV. 145 (1999).
100. George J. Annas, Patients' Rights in Managed Care- Exit, Voice, and Choice, 337 NEW ENG. J. MED. 210 (1997);
101. Walter A. Zelman, Consumer Protection in Managed Care: Finding the Balance, 16 HEALTH AFF. 158, 158 (1997);
102. Marc A. Rodwin, Consumer Protection and Managed Care: Issues Reform Proposals, and Trade-Offs, 32 HOUS. L. REV. 1319 (1996);
103. David Mechanic & Mark Schlesinger, The Impact of Managed Care on Patients' Trust in Medical Care and Their Physicians, 275 JAMA 1693 (1996);
104. Ezekiel J. Emanuel & Nancy N. Dubler, Preserving the Physician-Patient Relationship in the Era of Managed Care, 273 JAMA 323 (1995);
105. M. Gregg Bloche, Consumer-Directed Health Care, 355 NEW ENG. J. MED. 1756, 1756(2006).
106. Jerry Avorn, Debate about Funding Comparative-Effectiveness Research, 360 NEW ENG. J.MED. 1927, 1928-29(2009).